

West Midlands - Edgbaston Research Ethics Committee

2 Redman Place
Stratford
London
E20 1JQ

**Please note: This is the
favourable opinion of the
REC only and does not allow
you to start your study at NHS
sites in England until you
receive HRA Approval**

28 August 2025

Philip Bath
University of Nottingham
D floor, South block
Queen's Medical Centre
Derby Road
Nottingham
NG7 2UH

Dear Philip Bath

Study title:	CerebroVascular Disease-Cognition (CVD-Cog) phase-2 trial in non-lacunar ischaemic stroke with cerebral small vessel disease
REC reference:	25/WM/0144
Protocol number:	25017
EudraCT number:	
IRAS project ID:	1011543

Thank you for your letter of 20th August 2025, responding to the Research Ethics Committee's (REC) request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair.

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation as revised, subject to the conditions specified below.

Good practice principles and responsibilities

The [UK Policy Framework for Health and Social Care Research](#) sets out principles of good practice in the management and conduct of health and social care research. It also outlines the responsibilities of individuals and organisations, including those related to the four elements of [research transparency](#):

1. [registering research studies](#)
2. [reporting results](#)
3. [informing participants](#)
4. [sharing study data and tissue](#)

Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or NHS management permission (in Scotland) should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for HRA and HCRW Approval (England and Wales)/ NHS permission for research is available in the Integrated Research Application System.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations

Registration of Clinical Trials

All research should be registered in a publicly accessible database and we expect all researchers, research sponsors and others to meet this fundamental best practice standard.

It is a condition of the REC favourable opinion that **all clinical trials are registered** on a public registry before the first participant is recruited and no later than six weeks after. For this purpose, 'clinical trials' are defined as:

- clinical trial of an investigational medicinal product

- clinical investigation or other study of a medical device
- combined trial of an investigational medicinal product and an investigational medical device
- other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice.

A 'public registry' means any registry on the WHO list of primary registries or the ICMJE list of registries provided the registry facilitates public access to information about the UK trial.

Failure to register a clinical trial is a breach of these approval conditions, unless a deferral has been agreed by the HRA (for more information on registration and requesting a deferral see: [Research registration and research project identifiers](#)).

Where a deferral is agreed we expect the sponsor to publish a [minimal record](#) on a publicly accessible registry. When the deferral period ends, the sponsor should publish the full record on the same registry, to fulfil the condition of the REC favourable opinion.

If you have not already included registration details in your IRAS application form you should notify the REC of the registration details as soon as possible.

CTIMPs submitted for combined review via IRAS will have [study information](#) sent to the [ISRCTN registry](#) to facilitate registration unless a deferral has been requested or it has been indicated in the application that the trial is registered, or will be registered, on [ClinicalTrials.gov](#).

The lawful basis for processing your personal data for this purpose is official authority under the NHS Care Act 2014 (for further information please see our [privacy notice](#)).

Where the study is registered on ClinicalTrials.gov, please inform deferrals@hra.nhs.uk and the Research Ethics Committee (REC) which issued the final ethical opinion so that our records can be updated.

Publication of Your Research Summary

We will publish your research summary for the above study on the research summaries section of our website, together with your contact details, no earlier than three months from the date of this favourable opinion letter. Where a deferral is agreed, [a minimum research summary](#) will still be published in [the research summaries database](#). At the end of the deferral period, we will publish the [full research summary](#).

Should you wish to provide a substitute contact point, make a request to defer, or require further information, please visit: [Research summaries - Health Research Authority \(hra.nhs.uk\)](#)

Clinical trial authorisation must be obtained from the Medicines and Healthcare products Regulatory Agency (MHRA).

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

After ethical review: Reporting requirements

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study, including early termination of the study
- Final report
- Reporting results

The latest guidance on these topics can be found at [Managing your approval - Health Research Authority \(hra.nhs.uk\)](https://hra.nhs.uk/Managing-your-approval-Health-Research-Authority)

Ethical review of research sites

NHS/HSC sites

The favourable opinion applies to all NHS/HSC sites taking part in the study, subject to confirmation of Capacity and Capability (in England, Northern Ireland and Wales) or management permission (in Scotland) being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS/HSC sites

I am pleased to confirm that the favourable opinion applies to any non-NHS/HSC sites listed in the application, subject to site management permission being obtained prior to the start of the study at the site.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Cover Letter [Cover letter]	1.0	24 June 2025
EudraCT PDF [Medicines Information]		20 August 2025
GP/consultant information sheets or letters [GP letter - clean]	1.1	25 July 2025
GP/consultant information sheets or letters [GP letter - tracked]	1.1	25 July 2025
Investigator Brochure/SmPC [SmPC ISMN]	1.0	01 January 2018
Investigator Brochure/SmPC [SmPC ISMN XL]	1.0	09 April 2024
Investigator Brochure/SmPC [SmPC cilostazol]	1.0	09 March 2020
Letter from funder [Funding letter]	1.0	31 January 2025
Letter from sponsor [Sponsor letter]	1.0	24 June 2025
Miscellaneous [Telephone discussion record]	1.0	23 June 2025
Miscellaneous [Drug info sheet ISMN non XL]	1.0	23 June 2025
Miscellaneous [Drug info sheet cilostazol]	1.0	23 June 2025
Miscellaneous [Drug info sheet ISMN XL]	1.0	23 June 2025

Miscellaneous [Drug info sheet ISMN XL & Cilostazol]	1.0	23 June 2025
Miscellaneous [Drug info sheet ISMN & Cilostazol]	1.0	23 June 2025
Miscellaneous [Trial delegation log]	1.0	23 June 2025
Miscellaneous [Lay summary]	1.1	08 July 2025
Miscellaneous [Poster - updated]	1.1	25 July 2025
Miscellaneous [Consent to contact - clean]	1.1	25 July 2025
Miscellaneous [Consent to contact form - tracked]	1.1	25 July 2025
Participant information and informed consent form [PIS RIS appendices]	1.0	23 June 2025
Participant information and informed consent form [Participant Informed Consent]	1.0	23 June 2025
Participant information and informed consent form [Participant Informant contact details]	1.0	23 June 2025
Participant information and informed consent form [Informant consent to contact]	1.0	23 June 2025
Participant information and informed consent form [Informant information sheet - tracked]	1.1	25 July 2025
Participant information and informed consent form [Informant information sheet - clean]	1.1	25 July 2025
Participant information and informed consent form [PIS - clean]	1.1	25 July 2025
Participant information and informed consent form [PIS - tracked]	1.1	25 July 2025
Participant information and informed consent form [Legal rep information sheet - tracked]	1.1	25 July 2025
Participant information and informed consent form [Legal rep information sheet - clean]	1.1	25 July 2025
Participant information and informed consent form [Legal rep informed consent - tracked]	1.1	25 July 2025
Participant information and informed consent form [Legal rep informed consent - clean]	1.1	25 July 2025
Participant information and informed consent form [Contraception information sheet - clean]	1.1	25 July 2025
Participant information and informed consent form [Contraception information sheet - tracked]	1.1	25 July 2025
Participant information and informed consent form [Combined PIS and consent form - clean]	1.1	25 July 2025
Participant information and informed consent form [Combined PIS and consent form - tracked]	1.1	25 July 2025
Project Information - PDF [ProjectStudyInformation]		20 August 2025
Proof of Insurance [Insurance certificate]	1.0	01 August 2024
Protocol [Protocol - tracked]	1.1	25 July 2025
Protocol [Protocol - clean]	1.1	25 July 2025
REC Application Form [Ethics]		20 August 2025
Sample diary card/patient card [Patient drug card]	1.0	23 June 2025
Suitability of the investigator/Investigator CV [CI CV]	1.0	19 March 2025

Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: [Quality assurance - Health Research Authority \(hra.nhs.uk\)](https://www.hra.nhs.uk/quality-assurance)

HRA Learning

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities— see details at: [Learning - Health Research Authority \(hra.nhs.uk\)](https://www.hra.nhs.uk/learning)

IRAS project ID: 1011543 Please quote this number on all correspondence

With the Committee's best wishes for the success of this project.

Yours sincerely

pp
Darren Fletcher

**Professor John Marriott
Chair**

Email: edgbaston.rec@hra.nhs.uk

Enclosures: "After ethical review – guidance for
researchers"

Copy to: Philip Bath, University of Nottingham

Lead Nation - England: approvals@hra.nhs.uk

